Adamas Pharmaceuticals

$4.74
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.04 (+0.85%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell ADMS and other stocks, options, and ETFs commission-free!

About ADMS

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. The listed name for ADMS is Adamas Pharmaceuticals, Inc. Common Stock.

CEO
Neil F. McFarlane
Employees
138
Headquarters
Emeryville, California
Founded
2000
Market Cap
222.82M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.11M
High Today
$4.80
Low Today
$4.38
Open Price
$4.76
Volume
550.14K
52 Week High
$9.15
52 Week Low
$1.90

ADMS Earnings

-$0.99
-$0.78
-$0.58
-$0.37
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
-$0.51 per share
Actual
-$0.64 per share
Replay Earnings Call

You May Also Like

XIN
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure